CA2383220A1 - Controlled release pellet formulation - Google Patents

Controlled release pellet formulation Download PDF

Info

Publication number
CA2383220A1
CA2383220A1 CA002383220A CA2383220A CA2383220A1 CA 2383220 A1 CA2383220 A1 CA 2383220A1 CA 002383220 A CA002383220 A CA 002383220A CA 2383220 A CA2383220 A CA 2383220A CA 2383220 A1 CA2383220 A1 CA 2383220A1
Authority
CA
Canada
Prior art keywords
release
water
present
insoluble
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002383220A
Other languages
French (fr)
Other versions
CA2383220C (en
Inventor
Nirmal Mulye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nostrum Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383220A1 publication Critical patent/CA2383220A1/en
Application granted granted Critical
Publication of CA2383220C publication Critical patent/CA2383220C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

The present invention describes an aqueous pharmaceutical coating formulation which can be used for coating core elements containing one or more medicaments to achieve controlled release. The coated pharmaceutical formulation provides a release of medicaments in a controlled manner at highly acidic environment such as that of stomach and shows relatively faster release in media with basic pH such as that of the intestine. The coating composition is a heterogenous mixture which comprises (a) at least 75 % by weight of a water insoluble polymer which is insoluble in both acidic as well as basic pH; and (b) 1 to 25 % by weight of an enteric polymer which is substantially insoluble in water at a pH
below 4.5 and which is substantially soluble in water at a pH between above about 6.0, said enteric polymer and water insoluble polymer being present in an amount effective to control the release of said medicament. The pharmaceutical composition comprises a solid medicament present in effective amounts and the coating composition thereover.
CA002383220A 1999-09-02 2000-08-30 Controlled release pellet formulation Expired - Fee Related CA2383220C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15211599P 1999-09-02 1999-09-02
US60/152,115 1999-09-02
PCT/US2000/040783 WO2001015668A1 (en) 1999-09-02 2000-08-30 Controlled release pellet formulation

Publications (2)

Publication Number Publication Date
CA2383220A1 true CA2383220A1 (en) 2001-03-08
CA2383220C CA2383220C (en) 2009-11-03

Family

ID=22541572

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383220A Expired - Fee Related CA2383220C (en) 1999-09-02 2000-08-30 Controlled release pellet formulation

Country Status (12)

Country Link
US (2) US6475493B1 (en)
EP (1) EP1207860B1 (en)
JP (1) JP2003508422A (en)
AT (1) ATE376414T1 (en)
AU (1) AU781048B2 (en)
BR (1) BR0013720A (en)
CA (1) CA2383220C (en)
DE (1) DE60036874T2 (en)
ES (1) ES2295062T3 (en)
NZ (1) NZ517465A (en)
PT (1) PT1207860E (en)
WO (1) WO2001015668A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170195A1 (en) * 2014-05-03 2015-11-12 GORREPATI, Navaneeta Krishna Hydrazaline hydrochloride pellets and its preparation method

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
EP2060253A1 (en) 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
US8257744B2 (en) * 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
DE10211289A1 (en) 2002-03-14 2003-09-25 Basf Ag Combination of polyvinyl acetate from water-insoluble, acid-insoluble or alkali-insoluble polymers for the production of film coatings with very controlled release and high stability
WO2003096874A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
DE10260919A1 (en) * 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Process for the preparation of coated dosage forms and dietary supplements with concentration gradients in the coating
DE10260921A1 (en) * 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Process for coating substrates for pharmaceutical applications with a mixture of two film-forming coating agents
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
WO2004096208A1 (en) * 2003-04-25 2004-11-11 Mitsubishi Pharma Corporation Composition for oral administration containing alkylene dioxybenzene derivative
EP1680098A4 (en) * 2003-11-04 2012-06-13 Supernus Pharmaceuticals Inc Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms
EP1680100A4 (en) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc Compositions of quaternary ammonium containing bioavailability enhancers
EP2210605B1 (en) * 2003-11-04 2017-03-01 TCD Royalty Sub, LLC Once daily dosage forms of trospium
US20050106253A1 (en) * 2003-11-13 2005-05-19 Platteeuw Johannes J. Pharmaceutical pellets comprising tamsulosin
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US7989452B2 (en) * 2003-12-23 2011-08-02 Bioniche Teoranta Stable hydrazalazine pharmaceutical compositions
US20080286253A1 (en) * 2004-02-09 2008-11-20 Transfert Plus Societe En Commandite Composition Comprising Polymeric Material And Uses Thereof
KR100615952B1 (en) * 2004-05-27 2006-08-28 한국화학연구원 Controlled released type drug delivery system
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
AU2005320547B2 (en) 2004-12-27 2009-02-05 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070071819A1 (en) * 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
EP1915137B8 (en) 2005-08-10 2013-09-11 ADD Advanced Drug Delivery Technologies, Ltd. Oral preparation with controlled release
US8394812B2 (en) 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
WO2007025005A2 (en) 2005-08-24 2007-03-01 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
US20070048373A1 (en) 2005-08-30 2007-03-01 Cima Labs Inc. Dried milled granulate and methods
EP2298324A1 (en) * 2006-01-24 2011-03-23 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
RU2428176C2 (en) * 2006-01-27 2011-09-10 Юранд, Инк. Systems of medication delivery, containing weak-base medications and organic acids
JP5649784B2 (en) * 2006-02-07 2015-01-07 エフ エム シー コーポレーションＦｍｃ Ｃｏｒｐｏｒａｔｉｏｎ Composition, method for coating substrate with composition, coated substrate, product, film, pellet, tablet and capsule
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
EP1872779A1 (en) * 2006-06-28 2008-01-02 Oramon Arzneimittel GmbH Stable multiparticulate pharmaceutical composition comprising tri-and tetracyclic antidepressants
BRPI0719280A2 (en) 2006-11-27 2014-03-11 Lundbeck & Co As H COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR MODULATING THE ACTIVITY OF A P2X7 IN VITRO RECEIVER AND IN A PATIENT, TO TREAT A CONDITION RESPONSIBLE FOR P2X7 RECEIVER MODULATION IN A PATIENT, TO INHIBIT THE DEVELOPMENT OF A GALLULLE CELL IN A PITCH TO DETERMINE THE PRESENCE OR ABSENCE OF P2X7 RECEIVER IN A SAMPLE, PACKAGED PHARMACEUTICAL PREPARATION, METHOD FOR TREATING OR PREVENTING CIRROSIS IN A PATIENT, AND USING A COMPOUND.
DK2064222T3 (en) 2007-04-02 2014-07-21 Theracos Inc Benzylic glycoside derivatives and methods for their use
US20080268047A1 (en) * 2007-04-24 2008-10-30 Xavier University Of Louisiana Controlled Release Multiple Layer Coatings
WO2009026537A1 (en) 2007-08-23 2009-02-26 Theracos, Inc. Benzylbenzene derivatives and methods of use
US20090136650A1 (en) * 2007-09-18 2009-05-28 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20090074944A1 (en) * 2007-09-18 2009-03-19 Viva Pharmaceuticals Inc. Enteric coatings for orally ingestible compositions
US20110091566A1 (en) * 2007-09-25 2011-04-21 Nirmal Mulye Controlled release pharmaceutical compositions
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
BRPI0909185A2 (en) 2008-03-20 2015-08-25 Virun Inc Vitamin E derivative and its uses
US8282977B2 (en) 2008-03-20 2012-10-09 Virun, Inc. Compositions containing non-polar compounds
BRPI0916769A2 (en) 2008-07-15 2017-09-26 Theracos Inc deuterated benzylbenzene derivatives and methods of use
ES2599330T3 (en) 2008-08-22 2017-02-01 Theracos Sub, Llc Process for the preparation of SGLT2 inhibitors
CN102238946B (en) * 2008-11-07 2014-11-26 株式会社三养生物制药 Pharmaceutical composition for the controlled release of methylphenidate
EP2379561B1 (en) 2008-11-25 2015-11-04 University Of Rochester Mlk inhibitors and methods of use
KR101152977B1 (en) * 2009-12-14 2012-06-11 근화제약주식회사 Pharmaceutical Formulation Pharmaceutical Formulation
KR101622441B1 (en) 2010-03-23 2016-05-18 버런, 아이엔씨. Nanoemulsion including sucrose fatty acid ester
CN103153994B (en) 2010-05-24 2016-02-10 罗切斯特大学 Bicyclic heteroaryl kinase inhibitor and using method
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
IT1401146B1 (en) * 2010-07-27 2013-07-12 Gnosis Spa COMPOSITION INCLUDING SHELLAC AND / OR HIS SALT AND GLYCOLATED SODIUM STARCH
US20120039999A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
PL2672981T3 (en) 2011-02-11 2018-09-28 Zx Pharma, Llc Multiparticulate l-menthol formulations and related methods
ES2716865T3 (en) 2011-02-18 2019-06-17 Scripps Research Inst Directed differentiation of oligodendrocyte precursor cells to a myelinating cell target
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US8828426B2 (en) 2011-06-07 2014-09-09 Zx Pharma, Llc Multiparticulate L-carnitine compositions and related methods
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
LT2988824T (en) 2013-04-23 2019-02-25 Zx Pharma, Llc Enteric coated multiparticulate composition with proteinaceous subcoat
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5518694B2 (en) * 1973-04-02 1980-05-21
DE2336218C3 (en) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Oral dosage form
JPS587607B2 (en) * 1978-12-18 1983-02-10 信越化学工業株式会社 Method for manufacturing enteric-coated preparations
FR2471186A1 (en) 1979-12-10 1981-06-19 Roussel Uclaf NEW COLIC DELITESCENCE TABLETS AND THEIR PREPARATION PROCESS
DE3000979A1 (en) 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
DE3126703A1 (en) 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach BROMHEXIN RETARD FORM AND METHOD FOR THEIR PRODUCTION
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS59193831A (en) 1983-04-18 1984-11-02 Sankyo Co Ltd Preparation of enteric drug
DE3403329A1 (en) 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe PHARMACEUTICAL PRODUCT IN THE FORM OF PELLETS WITH CONTINUOUS, DELAYED DELIVERY OF ACTIVE SUBSTANCES
US4568559A (en) 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
JPS61501205A (en) 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション 8↓-chloro↓-6,11↓-dihydro↓-11↓-(4↓-piperidylidene)↓-5H↓-benzo[5,6]cyclohepta[1,2-b]pyridine and its salts, compounds thereof and pharmaceutical compositions containing these compounds.
US4568560A (en) * 1984-03-16 1986-02-04 Warner-Lambert Company Encapsulated fragrances and flavors and process therefor
GB8414220D0 (en) 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8427218D0 (en) 1984-10-27 1984-12-05 Scras Pyridine derivatives
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
DE3524337A1 (en) * 1985-07-08 1987-01-08 Roehm Gmbh MEDICINAL PACKAGING
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
LU86077A1 (en) 1985-09-18 1987-04-02 Pharlyse Sa NEW GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THESE NEW GALENIC FORMS
LU86099A1 (en) 1985-09-30 1987-04-02 Pharlyse EXTENDED RELEASE GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THEM
US5238686A (en) 1986-03-27 1993-08-24 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4904474A (en) 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US5277916A (en) 1988-02-01 1994-01-11 F. H. Faulding & Co., Ltd. Tetracycline dosage form
US5472710A (en) 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5330766A (en) 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
ATE124864T1 (en) * 1989-03-10 1995-07-15 Yamanouchi Pharma Co Ltd COATING MATERIAL THAT CONTROLLS THE ACTIVE INGREDIENTS RELEASE FOR LONG-ACTING FORMULATIONS.
US5026559A (en) 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5540945A (en) 1989-05-11 1996-07-30 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
US5084287A (en) 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
JP2773959B2 (en) 1990-07-10 1998-07-09 信越化学工業株式会社 Colon release solid preparation
US5288505A (en) 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
JPH07509702A (en) 1992-08-05 1995-10-26 エフ・エイチ・フォールディング・アンド・カンパニー・リミテッド pellet drug composition
JP2916978B2 (en) 1993-08-25 1999-07-05 エスエス製薬株式会社 Controlled release initiation type formulation
JPH08143476A (en) * 1994-11-18 1996-06-04 Japan Tobacco Inc Medicinal agent release-controlling membrane and solid preparation
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
JP3611456B2 (en) * 1997-09-30 2005-01-19 日研化学株式会社 Theophylline sustained release tablets

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170195A1 (en) * 2014-05-03 2015-11-12 GORREPATI, Navaneeta Krishna Hydrazaline hydrochloride pellets and its preparation method

Also Published As

Publication number Publication date
EP1207860A4 (en) 2005-07-13
CA2383220C (en) 2009-11-03
DE60036874T2 (en) 2008-06-26
BR0013720A (en) 2002-07-23
AU781048B2 (en) 2005-05-05
WO2001015668A1 (en) 2001-03-08
ES2295062T3 (en) 2008-04-16
AU1249201A (en) 2001-03-26
DE60036874D1 (en) 2007-12-06
PT1207860E (en) 2008-01-24
NZ517465A (en) 2003-10-31
JP2003508422A (en) 2003-03-04
EP1207860B1 (en) 2007-10-24
US20020192285A1 (en) 2002-12-19
US6635680B2 (en) 2003-10-21
EP1207860A1 (en) 2002-05-29
ATE376414T1 (en) 2007-11-15
US6475493B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
CA2383220A1 (en) Controlled release pellet formulation
US5639476A (en) Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA1303504C (en) Pharmaceutical formulation containing acrivastine
US7070806B2 (en) Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2181502A1 (en) Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
US20030180352A1 (en) Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CA2141582A1 (en) Pelletised pharmaceutical composition
CA2306103A1 (en) Novel once-a-day controlled release sulfonylurea formulation
BR0103033A (en) Pharmaceutical particles of masked flavor
ATE406872T1 (en) COUGH REMEDIES ADMINISTERED BY ION EXCHANGE RESINS
CA2312710A1 (en) Sustained release formulation containing three different types of polymers and tablet formed therefrom
IL150696A0 (en) Pharmaceutical compositions containing benzimidazole derivatives and processes for the manufacture thereof
PL356962A1 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
IE882295L (en) Controlled release formulation
CA2332922A1 (en) Enteric coated pharmaceutical composition and method of manufacturing
WO2006044202A3 (en) Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
CA2400567A1 (en) Tamper-resistant oral opioid agonist formulations
IE861671L (en) Stable solid dosage forms with elastic film coating
EP1086694A3 (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
CA2377916A1 (en) Taste masked pharmaceutical liquid formulations
EP0377517A3 (en) Theophylline dosage form
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
WO1998029095A3 (en) Sustained release cisapride mini-tablet formulation
CA2299423A1 (en) Taste-masked pharmaceutical composition
WO1999042087A3 (en) Controlled release potassium chloride pellet based pharmaceutical compositions having a high active ingredient content

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20110830